Y-mAbs Therapeutics, Inc.

YMAB

US9842411095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
12.28 ^USD	-4.58%		-28.40%	+80.06%

05-08	Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
05-07	Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	MT

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

November 13, 2023 at 09:05 pm

Y-mAbs Therapeutics, Inc. reiterated financial guidance for the year 2023. The company reiterating anticipated DANYELZA® net product revenues of between $80 million and $85 million.

Latest news about Y-mAbs Therapeutics, Inc.

Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	05-07	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024	04-29	CI
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	03-14	MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	03-14	CI
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	03-14	CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	03-06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	03-04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	03-04	MT
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	03-04	CI
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	03-04	MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024	03-01
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	03-01	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	02-29	MT
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	02-29	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	02-20	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	02-12	MT
Transcript : Y-mAbs Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	01-11
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	12-22	MT
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index	12-18	CI
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18	12-13	MT
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing	11-29	MT

Chart Y-mAbs Therapeutics, Inc.

Duration

Period

More charts

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

30/05/2024 - American Society of Clinical Oncology Annual Meeting - Poster Number: #10037

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Y-mAbs Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.28 USD

Average target price

21.33 USD

Spread / Average Target

+73.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Y-MABS THERAPEUTICS, INC.	+80.06%	539M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs